Abstract
Side effects of the distal gastrointestinal tract after NSAID use are common and more frequent than previously recognized. Increased mucosal permeability and mucosal inflammation are often silent but appear after NSAID treatment with most dual COX inhibitors. Other clinical manifestations include: anemia, occult blood loss, malabsorption, proteinloss, ileal dysfunction, diarrhea, mucosal ulceration and strictures due to diaphragm disease. More common complications are lower gastrointestinal bleeding and perforation, which represent at least one third of all gastrointestinal complications observed with NSAID use. Studies with selective COX-2 inhibitors have shown that, in the short term, these agents do not increase mucosal permeability or induce anemia due to occult bleeding and that, when compared to dual COX inhibitors, lower gastrointestinal complications may be reduced by 50%. In order to minimize the impact of these side effects, it is important to increase the current standards of suspicion by physicians who treat these patients, since drug discontinuation may further reduce damage, and clinical experience with agents that may prevent or treat distal tract damage is very limited. From this perspective, selective COX-2 inhibitors may be the drugs of choice in the high-risk patient that needs NSAIDs. Another important area of uncertainty is the impact of NSAID use in patients with inflammatory bowel diseases. Data from different animal models of inflammatory bowel disease suggest that inhibition of both COX-1 and COX-2 derived prostaglandins affects the severity of the mucosal inflammation. However, current epidemiological and clinical data are contradictory. Since many patients with inflammatory bowel diseases need NSAID treatment, clinicians should be aware of the problem and try to minimize or reduce NSAID exposure. Further studies are needed to define the effect of both non-selective NSAIDs and selective COX-2 inhibitors in these patients.
Keywords: Gastrointestinal, NSAID, COX-2 inhibitors
Current Pharmaceutical Design
Title: Clinical Implications of COX-1 and / or COX-2 Inhibition for the Distal Gastrointestinal Tract
Volume: 9 Issue: 27
Author(s): Angel Lanas, Julian Panes and Josep M. Pique
Affiliation:
Keywords: Gastrointestinal, NSAID, COX-2 inhibitors
Abstract: Side effects of the distal gastrointestinal tract after NSAID use are common and more frequent than previously recognized. Increased mucosal permeability and mucosal inflammation are often silent but appear after NSAID treatment with most dual COX inhibitors. Other clinical manifestations include: anemia, occult blood loss, malabsorption, proteinloss, ileal dysfunction, diarrhea, mucosal ulceration and strictures due to diaphragm disease. More common complications are lower gastrointestinal bleeding and perforation, which represent at least one third of all gastrointestinal complications observed with NSAID use. Studies with selective COX-2 inhibitors have shown that, in the short term, these agents do not increase mucosal permeability or induce anemia due to occult bleeding and that, when compared to dual COX inhibitors, lower gastrointestinal complications may be reduced by 50%. In order to minimize the impact of these side effects, it is important to increase the current standards of suspicion by physicians who treat these patients, since drug discontinuation may further reduce damage, and clinical experience with agents that may prevent or treat distal tract damage is very limited. From this perspective, selective COX-2 inhibitors may be the drugs of choice in the high-risk patient that needs NSAIDs. Another important area of uncertainty is the impact of NSAID use in patients with inflammatory bowel diseases. Data from different animal models of inflammatory bowel disease suggest that inhibition of both COX-1 and COX-2 derived prostaglandins affects the severity of the mucosal inflammation. However, current epidemiological and clinical data are contradictory. Since many patients with inflammatory bowel diseases need NSAID treatment, clinicians should be aware of the problem and try to minimize or reduce NSAID exposure. Further studies are needed to define the effect of both non-selective NSAIDs and selective COX-2 inhibitors in these patients.
Export Options
About this article
Cite this article as:
Lanas Angel, Panes Julian and Pique M. Josep, Clinical Implications of COX-1 and / or COX-2 Inhibition for the Distal Gastrointestinal Tract, Current Pharmaceutical Design 2003; 9 (27) . https://dx.doi.org/10.2174/1381612033453992
DOI https://dx.doi.org/10.2174/1381612033453992 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammatory Markers in Essential Hypertension: Potential Clinical Implications
Current Vascular Pharmacology Controversies in Glaucoma: Current Medical Treatment and Drug Development
Current Pharmaceutical Design Development and Characterization Pulsatile Microspheres of Nifedipine for Hypertension
Recent Patents on Drug Delivery & Formulation Effects of Medroxyprogesterone Acetate on the Risk of Cardiovascular Disease in Postmenopausal Women Receiving Estrogen
Vascular Disease Prevention (Discontinued) Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry Vascular Reactions of Iodinated X-Ray Contrast Media: Mechanisms and Possible Therapeutic Interventions
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design Cardiac SPECT-CT and PET-CT Imaging
Current Medical Imaging About Mechanism of Gas Transport Function and Side Reactions of Perfluorocarbon Nano-dispersions
Current Bionanotechnology (Discontinued) Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Design and Development of Novel Azo Prodrugs using Various Permutations and Combinations of 5- and 4-Aminosalicylic Acids for Inflammatory Bowel Disease: A Colon-Targeted Approach
Inflammation & Allergy - Drug Targets (Discontinued) Fractional Flow Reserve: Physiological Basis, Advantages and Limitations, and Potential Gender Differences
Current Cardiology Reviews Neurovascular Changes in Acute, sub-Acute and Chronic Mouse Models of Parkinson’s Disease
Current Neurovascular Research Olive Oil and Haemostasis: Platelet Function, Thrombogenesis and Fibrinolysis
Current Pharmaceutical Design Metabolic Effects of Renal Denervation
Current Clinical Pharmacology Synthesis and Biological Activity of 3-(2, 8, 9-Trioxa-aza-1-germatricyclo [3. 3. 3. 0]undecane-1-yl)-hydroxycinnamic Acids
Medicinal Chemistry Novel Biomarkers Assessing Endothelial Dysfunction: Role of microRNAs
Current Topics in Medicinal Chemistry Vasopressin in Liver Disease – Should We Turn On or Off?
Current Clinical Pharmacology Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy
Current Drug Targets The Role of “Eye Platelet Rich Plasma” (E-Prp) for Wound Healing in Ophthalmology
Current Pharmaceutical Biotechnology